176 related articles for article (PubMed ID: 22877947)
1. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.
Sandler A; Hirsh V; Reck M; von Pawel J; Akerley W; Johnson DH
Lung Cancer; 2012 Oct; 78(1):1-7. PubMed ID: 22877947
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
3. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
4. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients.
Srivastava G; Rana V; Wallace S; Taylor S; Debnam M; Feng L; Suki D; Karp D; Stewart D; Oh Y
J Thorac Oncol; 2009 Mar; 4(3):333-7. PubMed ID: 19190519
[TBL] [Abstract][Full Text] [Related]
5. Targeting angiogenesis for treatment of NSCLC brain metastases.
Schettino C; Bareschino MA; Rossi A; Maione P; Sacco PC; Colantuoni G; Rossi E; Gridelli C
Curr Cancer Drug Targets; 2012 Mar; 12(3):289-99. PubMed ID: 22229249
[TBL] [Abstract][Full Text] [Related]
6. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
7. What is the risk of intracranial bleeding during anti-VEGF therapy?
Carden CP; Larkin JM; Rosenthal MA
Neuro Oncol; 2008 Aug; 10(4):624-30. PubMed ID: 18539884
[TBL] [Abstract][Full Text] [Related]
8. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab safety in patients with central nervous system metastases.
Besse B; Lasserre SF; Compton P; Huang J; Augustus S; Rohr UP
Clin Cancer Res; 2010 Jan; 16(1):269-78. PubMed ID: 20028762
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology.
Morgensztern D; Govindan R
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S57-61. PubMed ID: 21885000
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
12. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
Gadgeel SM
Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor trap in non small cell lung cancer.
Riely GJ; Miller VA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4623-7. PubMed ID: 17671153
[TBL] [Abstract][Full Text] [Related]
14. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.
Bearz A; Garassino I; Tiseo M; Caffo O; Soto-Parra H; Boccalon M; Talamini R; Santoro A; Bartolotti M; Murgia V; Berretta M; Tirelli U
Lung Cancer; 2010 May; 68(2):264-8. PubMed ID: 19632738
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Subramanian J; Morgensztern D; Govindan R
Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
[TBL] [Abstract][Full Text] [Related]
16. Antivascular agents for non-small-cell lung cancer: current status and future directions.
Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
18. BIBF 1120 for the treatment of non-small cell lung cancer.
Reck M
Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
[TBL] [Abstract][Full Text] [Related]
19. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept in lung cancer.
Neal JW; Wakelee HA
Expert Opin Biol Ther; 2013 Jan; 13(1):115-20. PubMed ID: 23199019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
